Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Short term Debt (2024 - 2025)

Kura Oncology has reported Short term Debt over the past 2 years, most recently at $4.3 million for Q3 2025.

  • Quarterly Short term Debt rose 152.89% to $4.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2025, up 152.89% year-over-year, with the annual reading at $2.6 million for FY2024, N/A changed from the prior year.
  • Short term Debt was $4.3 million for Q3 2025 at Kura Oncology, up from $3.1 million in the prior quarter.
  • Over five years, Short term Debt peaked at $4.3 million in Q3 2025 and troughed at $847000.0 in Q2 2024.